Phase I Study Utilizing Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor Nivolumab for Relapsed/Refractory Lymphoma
Latest Information Update: 30 Aug 2024
At a glance
- Drugs Nivolumab (Primary) ; Immunotherapies
- Indications Diffuse large B cell lymphoma; Hodgkin's disease
- Focus Adverse reactions
- Acronyms SUSTAIN
Most Recent Events
- 28 Aug 2024 Planned primary completion date changed from 1 May 2024 to 1 May 2025.
- 19 Sep 2023 Planned End Date changed from 1 Nov 2023 to 1 May 2025.
- 19 Sep 2023 Planned primary completion date changed from 1 May 2023 to 1 May 2024.